Soligenix Inc. (SNGX) - Total Liabilities
Based on the latest financial reports, Soligenix Inc. (SNGX) has total liabilities worth $3.70 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Soligenix Inc. (SNGX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Soligenix Inc. - Total Liabilities Trend (1995–2024)
This chart illustrates how Soligenix Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SNGX asset base.
Soligenix Inc. Competitors by Total Liabilities
The table below lists competitors of Soligenix Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cash.Medien AG
HM:MF8
|
Germany | €861.26K |
|
Basin Energy Ltd
AU:BSN
|
Australia | AU$222.06K |
|
Techfast Holdings Bhd
KLSE:0084
|
Malaysia | RM5.07 Million |
|
Revelation Biosciences Inc
NASDAQ:REVB
|
USA | $2.43 Million |
|
GreenPower Motor Company Inc
NASDAQ:GP
|
USA | $40.31 Million |
|
Essentra PLC
LSE:ESNT
|
UK | GBX225.50 Million |
|
E-Home Household Service Holdings Ltd
NASDAQ:EJH
|
USA | $10.27 Million |
|
GGL Resources Corp
V:GGL
|
Canada | CA$35.30K |
Liability Composition Analysis (1995–2024)
This chart breaks down Soligenix Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Soligenix Inc. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Soligenix Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Soligenix Inc. (1995–2024)
The table below shows the annual total liabilities of Soligenix Inc. from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.85 Million | -33.35% |
| 2023-12-31 | $7.27 Million | -56.57% |
| 2022-12-31 | $16.75 Million | +3.74% |
| 2021-12-31 | $16.15 Million | -0.01% |
| 2020-12-31 | $16.15 Million | +155.60% |
| 2019-12-31 | $6.32 Million | +50.02% |
| 2018-12-31 | $4.21 Million | +30.39% |
| 2017-12-31 | $3.23 Million | +12.55% |
| 2016-12-31 | $2.87 Million | -61.25% |
| 2015-12-31 | $7.41 Million | +4.18% |
| 2014-12-31 | $7.11 Million | -29.17% |
| 2013-12-31 | $10.04 Million | +769.61% |
| 2012-12-31 | $1.15 Million | -19.45% |
| 2011-12-31 | $1.43 Million | -25.02% |
| 2010-12-31 | $1.91 Million | +57.91% |
| 2009-12-31 | $1.21 Million | -12.67% |
| 2008-12-31 | $1.39 Million | +16.10% |
| 2007-12-31 | $1.19 Million | -52.55% |
| 2006-12-31 | $2.52 Million | +36.37% |
| 2005-12-31 | $1.84 Million | -11.50% |
| 2004-12-31 | $2.08 Million | +106.90% |
| 2003-12-31 | $1.01 Million | -35.12% |
| 2002-12-31 | $1.55 Million | -88.64% |
| 2001-12-31 | $13.67 Million | +337.69% |
| 2000-12-31 | $3.12 Million | +54.93% |
| 1999-12-31 | $2.02 Million | +34.40% |
| 1998-12-31 | $1.50 Million | +114.29% |
| 1997-12-31 | $700.00K | +438.46% |
| 1996-12-31 | $130.00K | +126.15% |
| 1995-12-31 | $57.48K | -- |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the tre… Read more